1	Metabolomics strategy for diagnosing urinary tract infections
2	Daniel B. Gregson ^{1,2} [†] , Spencer D. Wildman ³ [†] , Carly C.Y. Chan ³ [†] , Dominique G. Bihan ³ , Ryan
3	A. Groves ³ , Raied Aburashed ³ Thomas Rydzak ³ , Keir Pittman ³ , Nicolas Van Bavel ³ , and Ian A.
4	Lewis ³ *
5	¹ Department of Pathology and Laboratory Medicine, Cumming School of Medicine, University
6	of Calgary, Calgary, AB, T2N 1N4, Canada
7	² Department of Medicine, Cumming School of Medicine, University of Calgary, Calgary, AB,
8	T2N 1N4, Canada
9	³ Alberta Centre for Advanced Diagnostics, Department of Biological Science, University of
10	Calgary, Calgary, AB, T2N 1N4, Canada
11	
12	† Equal contributions
13	*Corresponding author: Ian A. Lewis
14 15 16 17 18 19	Department of Biological Sciences 2500 University Drive NW Calgary, AB, Canada T2N 1N4 1-403-220-4366 ian.lewis2@ucalgary.ca
20	
21	
22	
23	
24 25	

26 Abstract

Metabolomics has emerged as a mainstream approach for investigating complex metabolic phenotypes but has yet to be integrated into routine clinical diagnostics. Metabolomics-based diagnosis of urinary tract infections (UTIs) is a logical application of this technology since microbial waste products are concentrated in the bladder and thus could be suitable markers of infection. We conducted an untargeted metabolomics screen of clinical specimens from patients with suspected UTIs and identified two metabolites, agmatine and N6-methyladenine, that are predictive of culture positive samples. We developed a 3.2-minute LC-MS assay to quantify these metabolites and showed that agmatine and N6-methyladenine correctly identify UTIs caused by 13 Enterobacterales species and 3 non-Enterobacterales species, accounting for over 90% of infections (agmatine AUC > 0.95; N6-methyladenine AUC > 0.89). These markers were robust predictors across two blinded cohorts totaling 1,629 patient samples. These findings demonstrate the potential utility of metabolomics in clinical diagnostics for rapidly detecting UTIs.

52 Main Text

53 Introduction

54 Infections are caused by a wide range of microbes that, like all organisms, consume nutrients 55 and secrete metabolic waste products. These microbial metabolites can be highly abundant at the site of infection¹ and thus, could potentially serve as targets for a metabolism-based diagnostic 56 57 strategy. Urinary tract infections (UTIs) are particularly amenable to this metabolic diagnostic 58 approach because microbial metabolites are concentrated in the bladder and can be easily detected 59 by liquid chromatography mass spectrometry (LC-MS) analysis of patient urine. Escherichia coli, the most common UTI pathogen, produces a variety of diamines, polyamines, and acylated 60 61 conjugates of these molecules that are not typically found in human urine. These molecules have been reported as potential UTI biomarkers for over three decades^{2,3}, with more recent work 62 suggesting that these amine-linked molecules may play a role in resistance to nitrosative stress in 63 the bladder 4,5 . 64

65 Although microbial metabolites have been recognized as potential diagnostic targets, they have yet to be translated into a clinical diagnostic tool. The reason for this is threefold: 1) concentrations 66 of the microbial polyamines are quite variable in urine⁶ and are thus of borderline utility for 67 diagnostic purposes, 2) only biomarkers of E. coli have been reported thus far, which is problematic 68 69 because it is only one of many UTI-causing organisms⁷, and 3) LC-MS has only recently become sufficiently robust to serve as a practical diagnostic platform. The primary objective of this study 70 71 was to conduct a systematic analysis of microbial metabolites found in urine from symptomatic 72 UTI patients to identify any molecules with sufficient predictive power to enable rapid, metabolic-73 based diagnostics. Using an untargeted LC-MS metabolomics approach, we identified two novel 74 biomarkers that report on a wide transect of UTI pathogens. We then assess the potential utility of 75 metabolomics-based UTI screening in two blinded cohorts totaling 1,629 urine samples.

76 **Results**

77 UTI biomarker discovery

78 UTIs are diagnosed based on patient symptoms supported by laboratory diagnostic tests. These 79 clinical tests include culturing urine specimens for 18 hours to identify patients with significant bacteriuria (defined by Alberta Precision Laboratories guidelines as specimens with $>10^7$ CFU/L)⁸. 80 Microbial catabolites present in the urine could potentially provide a culture-independent 81 mechanism for rapidly identifying these positive samples. To identify potential biomarkers in these 82 83 urine specimens, untargeted metabolomics analyses (Figure 1a; Supporting Dataset 1) of 77 84 culture-positive urine samples and 33 culture negative samples ($<10^7$ CFU/L)—all collected from 85 symptomatic patients—were conducted using LC-MS. The most diagnostic features in this dataset, 86 as judged by area under the curve (AUC) of the receiver operating characteristic (ROC) curve, were 87 m/z 114.1025 (AUC=0.98), m/z 131.1289 (AUC=0.89), and m/z 150.0772 (AUC=0.91; Figure 1b; 88 Supporting Dataset 1). The first two of these untargeted signals were putatively assigned to agmatine, a product of arginine metabolism⁹, and the third was assigned to N6-methyladenine, a 89 modified nucleobase found in prokaryotes¹⁰. These assignments were validated by LC-MS/MS 90 91 fragmentation patterns as well as co-elution of the target signal with analytical standards (Figure 92 1c,d).

93 Validation of agmatine as a UTI biomarker

Although both agmatine and N6-methyladenine were predictive of positive urine cultures, the levels of these metabolites were not uniform across UTI-causing pathogens. Infections caused by the most prominent UTI-causing *Enterobacterales* species, such as *E. coli*, were associated with elevated agmatine, whereas N6-methyladenine levels were elevated in infections caused by a small number of non-*Enterobacterales* species (Supporting Dataset 1). To better understand these species-specific phenotypes, the performance of agmatine was assessed using 519 urine cultures that were taken directly from a clinical diagnostic pipeline. Stable isotope labeled [U-¹³C]agmatine

101 was spiked into samples, samples were purified using solid phase extraction (SPE) on a silica column, and agmatine and [U-13C]agmatine levels were measured using a targeted mass 102 103 spectrometry method. Agmatine concentrations were thus quantifiable based on the signal ratio 104 between isotope-labeled and native species. As expected, urinary agmatine levels were closely 105 correlated with the presence of uropathogenic *Enterobacterales*, whereas culture-negative urine 106 samples contained no detectable agmatine (AUC of 0.99, CI of 0.98 - 1.00; Fig 2a; Supporting Dataset 2). Moreover, we found that a diagnostic threshold of 174 nM agmatine was predictive of 107 infections caused by E. coli, Citrobacter species, Enterobacter species, Klebsiella species, and 108 109 Proteus mirabilis (sensitivity, 94%; specificity, 97%; PPV, 0.96; NPV, 0.95; Figure 2a), all of which showed significantly higher agmatine levels than urine from culture negative patients (p =110 2.15×10^{-45} , $p = 1.43 \times 10^{-49}$, $p = 2.22 \times 10^{-52}$, $p = 3.85 \times 10^{-40}$, $p = 5.91 \times 10^{-47}$, respectively via two-tail 111 112 unequal variance Welch T-test relative to culture negative urine samples; Supporting Dataset 2).

113 Validation of N6-methyladenine as a UTI biomarker

Although the agmatine-based screening approach captures most UTI infections caused by 114 *Enterobacterales* species—which collectively account for >83% of UTIs⁷—it did not capture those 115 caused by enterococci, staphylococci, or other less common species (e.g Group B strep, 116 117 Pseudomonas aeruginosa, Aerococcus urinae, Candida albicans). Since these pathogens account 118 for a small percentage of all UTIs, we prospectively collected a targeted cohort of 71 non-119 Enterobacterales UTI specimens along with 24 negative controls. LC-MS analyses showed that 120 N6-methyladenine signals correctly differentiated culture-negative urine samples from this selected 121 cohort of infections (sensitivity, 91%; specificity, 83%; PPV, 0.84; NPV, 0.91; Figure 2b; 122 Supporting Dataset 3). However, there were clear species-to-species differences in the quality of 123 these metabolic diagnostics, with Staphylococcus aureus, Staphylococcus saprophyticus, and 124 Aerococcus urinae showing the most significant differences after Bonferroni correction from multiple hypothesis testing ($p = 1.26 \times 10^{-3}$, $p = 3.22 \times 10^{-4}$, $p = 3.72 \times 10^{-6}$, respectively via two-tail 125 5

unequal variance Welch T-test relative to culture negative urine samples; Figure 2b; Supporting
Dataset 4). N6-methyladenine levels were predictive of these three non-*Enterobacterales* species
(AUC of 0.80; CI, 0.69 – 0.92; Supporting Dataset 3). N6-methyladenine is part of a wider family
of adenine derivatives, including 1-methyladenine and adenine, which were elevated in the urine
of these UTI patients (Supporting Dataset 4). However, our LC-MS analyses showed that the
diagnostic performance of these additional markers was lower, and these compounds were linked
to fewer species than N6-methyladenine.

133 Validation of microbial metabolic capacity

134 Agmatine and N6-methyladenine in the urine of UTI patients could potentially originate from microbial or human metabolism. To better understand the origin of these molecules, filter sterilized 135 136 urine was taken from healthy controls and was inoculated with E. coli and S. aureus isolates. In the case of the *E. coli* culture, 20 µM of ¹⁵N-labelled arginine (a physiologically relevant level 137 approximating the concentration of native urinary arginine) was added to the urine at the start of 138 139 the incubation. Throughout the incubation, isotope-labeled arginine levels progressively decreased while isotope-labeled agmatine was produced (Figure 2c). The appearance of isotope-labeled 140 141 agmatine is expected under these conditions due to the microbial arginine decarboxylase activity of E. coli⁹. Likewise, we screened the S. aureus cultures over 12 hours via LC-MS and observed 142 143 that N6-methyladenine was produced by these microbes when grown in filter-sterilized urine 144 (Figure 2c). In summary, the most diagnostic biomarkers observed in UTI specimens are readily produced by UTI pathogens grown in filter-sterilized urine, indicating that these metabolites are 145 146 naturally produced through microbial metabolic activity.

147 Urine specimens for UTI diagnostics are generally collected in outpatient clinics and delivered 148 to centralized microbiology testing labs. Sample transport logistics and other delays in analysis 149 could therefore complicate microbial diagnostics if microbes were allowed to grow. To control this, 150 urine specimens are collected in boric acid tubes, which inhibit microbial growth. To verify that

microbes stored in boric acid tubes will not produce our target metabolites, which could cause false positive results in specimens with sub-clinical bacterial levels ($< 10^7$ CFU/L), we screened for agmatine production in three reference strains of *E. coli* and four clinical isolates, in boric acid over 24 hours via LC-MS. In the absence of boric acid preservatives, agmatine levels reached a peak intensity after 7 hours and maintained elevated levels over the next 17 hours (Supplementary Figure 1a). In contrast, isolates stored in boric acid preservatives did not produce agmatine over the 24hour period (Supplementary Figure 1b).

158 Clinical Cohort 1

159 Although untargeted metabolomics is currently not used for clinical diagnostics, mass 160 spectrometry is a routine component of many diagnostic labs where it serves as a platform for 161 quantifying a range of biomolecules including steroid hormones, drugs of abuse, and metabolites that are linked to inborn errors of metabolism¹¹. Consequently, much of the requisite infrastructure 162 necessary for diagnosing UTIs via metabolic profiles can be found in diagnostic laboratories. 163 However, the instrumentation used for untargeted metabolomics analyses is quite different from 164 165 that employed in clinical settings. To demonstrate the feasibility of adapting our metabolomics 166 approach to routine clinical diagnostics, we developed a targeted diagnostics workflow using a 167 triple quadrupole LC-MS instrument that is commonly used for clinical mass spectrometry.

168 To determine the performance of this clinically-adapted UTI diagnostics approach, we 169 conducted a head-to-head performance evaluation of our LC-MS method versus results obtained via the traditional clinical microbiology approach¹². This cohort consisted of 587 urine specimens 170 submitted to Alberta Precision Laboratories (South Hub) over a 48-hour period. The demographics 171 of these specimens have been described previously⁷. Briefly, these samples were taken from the 172 173 greater Calgary metropolitan area where 74% of urine cultures are submitted from ambulatory out-174 patient visits, 18% from hospitalized patients, and 9% from nursing home residents. Females have 175 a 6-fold higher incidence rate of UTIs than males in this population. Importantly, Alberta follows

-0.98). Moreover, at the previously determined agmatine threshold of 174 nM, LC-MS diagnostics

had a 95% sensitivity and 86% specificity for predicting *Enterobacterales* infections (Figure 3,

181 Supporting Dataset 5). As expected, our culture-negative samples, those classified as being of

doubtful clinical significance (DCS; $<10^7$ CFU/L), and a small number of urine samples (<5%)

183 containing non-*Enterobacterales* microbes all had agmatine levels below the limit of detection.

184

185 *Clinical Cohort 2*

186 One limitation of our original targeted method is that it was specific to agmatine and thus could 187 not be expanded to the analysis of other urinary metabolites, including creatinine, a standard marker of urinary dilution^{14,15}. To address this limitation, we developed a "dilute and shoot" sample 188 189 preparation workflow coupled with a 3.2-minute LC-MS targeted assay for agmatine, N6-190 methyladenine, and creatinine. To enable accurate quantification of agmatine/N6-methyladenine 191 and creatinine, which are present at substantially different concentrations in urine (nM versus mM), 192 we used a higher dilution (1:200 final) than in the previous trial. Using this assay, we analyzed 1,042 urine specimens from suspect UTI cases. In this cohort, we again showed that urinary 193 194 agmatine concentrations over 174 nM is an accurate predictor of Enterobacterales infections (93% sensitivity; 90% specificity; PPV, 0.67; NPV, 0.98; Figure 4, Supporting Dataset 6). Moreover, we 195 196 showed that creatinine normalization had a slight negative impact on the performance of the assay 197 (AUC of 0.95, CI 0.93-0.97; versus 0.92, CI 0.89-0.95; for agmatine alone versus creatinine-198 normalized agmatine levels, respectively; Figure 4, Supplemental Dataset 6). N6-methlyadenine 199 levels were also found to be predictive of UTIs (AUC of 0.71, CI 0.69 - 0.74; inclusive of all species; Supplemental Dataset 6). As expected, the performance of N6-methlyadenine was 200

improved when analyses were restricted to the three known N6-methlyadenine producing species
(AUC, 0.89; CI, 0.75 - 1.0; Supporting Dataset 6, Supplementary Figure 2). In this restricted subcohort, a N6-methlyadenine concentration of 217 nM had a sensitivity of 0.78 and specificity of
0.79 for differentiating infections with *S. aureus*, *S. saprophyticus*, and *A. urinae* versus infections
with all other species and negative specimens (Supplementary Figure 2, Supporting Dataset 6). We
also tested the performance of a composite model using both agmatine and N6-methlyadenine

- 207 levels to predict infections. This combined model performed slightly worse than the agmatine-only
- 208 model as a generalized tool for detecting UTIs (inclusive of all species, AUC of 0.85 versus 0.78
- for the composite versus agmatine-only models, respectively; Supporting Dataset 6).
- 210

211 Discussion

212 UTIs are one of the most common bacterial infections and are responsible for over eight million healthcare visits per year in the U.S. alone^{16,17}. As a result, urine cultures are one of the 213 214 most common tests performed by microbiology reference labs (24–40% of all cultures analyzed)¹⁸. 215 The current diagnostic workflow used to process these samples follows a multi-day procedure that 216 includes: streaking urines on agar plates, incubation for 18 hours, colony counting, microbial identification via MALDI-TOF mass spectrometry, and antibiotic susceptibility testing¹². This long 217 218 diagnostic workflow (24-48 hours) encourages clinicians to prescribe antibiotics before lab results 219 are available. Given that up to 70% of suspected UTI cases collected by clinical testing facilities 220 are ultimately found to be culture negative, the current empiric antimicrobial prescribing practice leads to overprescribing and may contribute to the spread of antimicrobial resistance¹⁹⁻²¹. 221 Therefore, rapid diagnostic tools that can quickly identify patients with UTIs could enable more 222 precise antimicrobial prescribing practices²²⁻²⁴. 223

Herein, we used untargeted metabolomics to identify native biomarkers present in uncultured urine that robustly differentiate between culture negative and culture positive patients. Using these

226 untargeted data, we identified two predictive metabolites (agmatine and N6-methyladenine) that 227 are elevated in uncultured urine from patients who were later confirmed to have UTIs. We show 228 that these biomarkers are produced by UTI pathogens when they are cultured in urine and that an 229 agmatine concentration of 174 nM and N6-methyladenine concentration of 217 nM in urine corresponds with the clinical definition of bacteriuria $(>10^7 \text{ CFU/L})^8$. We developed a clinical LC-230 MS workflow to detect these molecules and demonstrated that these biomarkers are robust 231 predictors of UTIs in two independent cohorts consisting of 1,629 clinical specimens in total (AUC 232 233 > 0.95 and 0.89 for 13 Enterobacterales and 3 non-Enterobacterales species, respectively). 234 Collectively, these data show that metabolite levels present in uncultured urine can be used to 235 accurately reproduce the results generated by traditional urine culture and, therefore, could 236 potentially enable novel rapid UTI testing approaches.

237 The multiple independent trials we conducted over the course of this study provide some insights into leveraging metabolite biomarkers of UTIs. Firstly, our creatinine normalization study 238 239 showed that correcting metabolite levels to account for variability in urinary dilution does not 240 improve their diagnostic performance – if anything these corrections make things worse (Figure 4; 241 Supporting Dataset 6). This observation is consistent with our microbial culturing experiments, 242 which showed that agmatine and N6-methyladenine are normal microbial catabolites produced 243 when UTI pathogens are grown in urine. Thus, if agmatine and N6-methyladenine levels in patient 244 samples primarily result from microbial metabolism within the urinary tract, we would expect both the biomarker levels and planktonic bacterial density in the urine (in CFU/L) to be diluted in 245 parallel. Given that the clinical definition of bacteriuria is based on bacterial density⁸ it is 246 unsurprising that the microbially-produced catabolites we identified were most diagnostically 247 248 robust when their levels were not corrected for urinary dilution. This observation has practical implications: quantifying the abundant creatinine necessitated a higher dilution than is necessary 249 250 for quantifying the low-abundant agmatine and N6-methyladenine. This over-dilution diminished

the performance of our target markers in our final clinical cohort, as their signals were closer to the
LC-MS noise threshold. Thus, omitting creatinine normalization improves performance of our
assay.

254 Another practical observation from our final clinical cohort is that a mixed agmatine/N6methyladenine model for predicting infection performed slightly worse than an agmatine only 255 256 model (all cause UTI; mixed AUC 0.78, 0.74-0.81; agmatine only AUC 0.85, 0.82-0.88; Supporting 257 Dataset 6). The reason for this is that only 9 out of the 1,042 urine specimens (9 out of 277 positive 258 samples; 3.2%) in the final cohort were from infections with N6-methyladenine-producing 259 organisms. This prevalence is consistent with previous studies in the same region $(3.2\% \text{ vs } 2.1\%)^7$. Thus, screening samples via N6-methyladenine levels added false discovery, but minimal 260 additional sensitivity to the assay. This is a common problem in screening for rare events²⁵ and 261 262 suggests that an agmatine-only screening approach might be preferable.

263 One important consideration about the generalizability of our findings is that the mix of species 264 observed in clinical specimens will have a direct impact on the clinical performance of our 265 biomarker-based diagnostic approach. The proportions of species we observed are largely 266 consistent with those reported elsewhere with the exception of *S. saprophyticus* (an N6-267 methyladenine-producer), which was underrepresented relative to the North American average (1% 268 vs 5%)^{26,27}. Therefore, N6-methyladenine could potentially be of greater diagnostic value in other 269 health jurisdictions – especially in jurisdictions with a greater proportion of out-patient cases.

The robust performance of agmatine as a diagnostic marker for *Enterobacterales* infections across four separate cohorts suggests that this metabolite is a good candidate for clinical applications. As an LC-MS assay, agmatine screening could be used to rapidly identify patients with clinically significant bacteriuria. This screening approach is 18 hours faster than the traditional urine culture workflow and could accommodate thousands of analyses per day²⁸. Alternatively, agmatine screening for UTIs could also be enabled via point-of-care testing tools, such as lateral

flow assays, which could be made possible via existing commercial antibodies for agmatine²⁹. If such a point-of-care tool were made, it would complement existing dipstick-style UTI screening tests (i.e. nitrate and leucocyte esterase)³⁰. In this context, agmatine screening would be both favorable from a performance perspective (Supporting Dataset 7) and because the *Enterobacterales*-specific agmatine test could be used to help guide more precise prescribing decisions.

Although we demonstrate robust performance of our metabolomics-based UTI screening 282 concept, there are some important limitations of this strategy that warrant discussion. Firstly, the 283 284 biomarkers we identify here report bacteriuria (high levels of bacteria in the urine), not infection. 285 This distinction is important as asymptomatic bacteriuria is common and does not necessarily warrant antimicrobial therapy³¹. Thus, agmatine/N6-methaladenine screening would need to be 286 287 paired with symptomatic evaluation by a clinician to enable UTI diagnosis (i.e. following existing practice). Secondly, the gold-standard diagnostic workflow involves both species-level 288 289 identification of the pathogen and empiric antimicrobial susceptibility testing, neither of which is 290 possible with our screening approach alone. However, most UTIs are treated without supporting 291 lab data. Therefore, we envision agmatine/N6-methaladenine screening as a tool to improve 292 empiric prescribing practices rather than as a replacement for culture-based diagnostics. Thirdly, 293 the biomarkers we report here have clinically significant blind spots, especially in the context of 294 UTIs from hospitalised patients. New biomarkers covering Candida, Enterococcus, Pseudomonas, and group B Streptococcus must be identified if our proposed metabolism-based UTI screening 295 296 concept is to be applied to hospitalized patients. Despite these limitations, the agmatine/N6-297 methaladenine screening approach we introduce here is robust, reproducible over multiple 298 independent clinical cohorts, and could add significant value as a point-of-care or patient-near tool 299 to enable more precise empiric prescribing decisions for uncomplicated UTIs.

300

301

302 Methods

303 *Experimental design*

304 Untargeted analysis for biomarker discovery was performed directly on patient urine samples 305 (77 culture positive, 33 culture negative) using a Q Exactive[™] HF Hybrid Quadrupole-Orbitrap[™] 306 Mass Spectrometer. Putative biomarkers were identified using MS/MS analysis and matched to 307 standards using fragmentation spectra and retention times. To identify agmatine thresholds that 308 differentiate culture positive ($\geq 10^7$ CFU/L; n=240) versus culture negative urines (<10⁷ CFU/L; n=279), patient urines were spiked with a known concentration of labeled [U-¹³C]agmatine, 309 310 purified using solid phase extraction (SPE), and analyzed on the TSQ Quantum[™] Access MAX Triple Quadrupole Mass Spectrometer. Agmatine concentrations were quantified based on the 311 signal ratio between isotope-labeled and native species. Quantitative analyses of N6-methyladenine 312 313 were performed directly on patient urine samples (71 culture positive non-Enterobacterales, 24 culture negative) using external standards following analysis via the Q Exactive[™] HF platform. To 314 315 demonstrate that agmatine and N6-methyladenine originate from microbial metabolism, E. coli and 316 S. aureus were incubated in sterilized urine and production of biomarkers was monitored. Similarly, 317 to demonstrate that agmatine concentrations are proportional to microbial load, Mueller Hinton Medium was seeded with varying concentrations of *E*. *coli* (10^3 - 10^8 CFU/mL) and agmatine levels 318 were measured following a 6-hour incubation period. Inhibition of agmatine production by boric 319 acid was also monitored in filter sterilized urine seeded with E. coli during a 24-hour incubation 320 321 period. Two clinical trials were performed to validate discovered biomarkers. The first clinical trial 322 was performed using SPE purified urine samples (n=587) on the TSO QuantumTM. In the second 323 clinical trial (dilute and shoot approach), methods were developed to quantify agmatine, N6methyladenine, and creatinine directly in urine using a single injection. For these analyses, urine 324

from residual clinical urine samples (n=1,042) was analyzed after a 1:200 dilution (V:V in 50%
methanol final) using the TSQ Altis[™] triple quadrupole. The specific LC-MS methods for each
experiment are described below.

328 Urine sample collection

329 Mid-stream urine samples were collected from Alberta Precision Laboratories' (APL) 330 standardized urine analysis workflow, consisting of samples submitted for urine culture from 331 symptomatic ambulatory (74%), hospitalized (18%), and nursing home patients (9%) in the Calgary 332 metropolitan area. Age demographics are divided as follows: 20/1,000 for ages <1; <20/1,000 for 333 ages 1-59; 24/1,000 for ages 60-69; 32/1,000 for ages 70-79; 100/1,000 for ages 80-89; 851/1,000 334 for ages >90. Incidence rates in females are 30/1,000 and males are 5/1,000. Samples were de-335 identified prior to transfer to the study team. In brief, urine was plated either manually with a loop 336 or using automated equipment onto UriSelectTM Media (Bio-Rad, Canada) and incubated aerobically for 18 hours. Growth of bacteria was enumerated as per standard recommendations¹² 337 and colonies present in significant quantities were speciated using the Vitek[™] MS system 338 (bioMérieux, Canada). Residual samples from this standard diagnostic lab workflow were fixed 339 1:1 with 100% methanol within 48 hours post-receipt at APL, and then frozen at -80 °C. All samples 340 341 were thawed, centrifuged at $14,800 \times g$, and diluted ten-fold further into 50% HPLC-grade 342 methanol prior to LC-MS analysis. All samples were acquired under approval from Conjoint Health 343 Research Ethics Board certificate REB19-0442.

344 Untargeted mass spectrometry

Untargeted analysis of positive and negative urine samples was performed for UTI biomarker
 discovery and quantification of N6-methyladenine thresholds. Methods were adapted from
 previously published studies^{32–37}. Briefly, metabolic analyses were performed on a Q ExactiveTM
 HF Hybrid Quadrupole-OrbitrapTM Mass Spectrometer (Thermo-Fisher) coupled to a VanquishTM

349 UHPLC System (Thermo-Fisher). Chromatographic separation of metabolites was performed on 350 Syncronis HILIC UHPLC column (2.1mm x 100 mm x 1.7 µm, Thermo-Fisher) at a flow rate of 351 600 μL/min using a binary solvent system: solvent A, 20 mM ammonium formate pH 3.0 in mass 352 spectrometry grade H₂O and solvent B, mass spectrometry grade acetonitrile with 0.1% formic acid 353 (% v/v). For initial biomarker discovery experiments, the following 15-minute gradient was used: 0-2 min, 100% B; 2-7 min, 100-80% B; 7-10 min, 80-5% B; 10-12 min, 5% B; 12-13 min, 5-354 100% B; 13–15 min, 100% B. The mass spectrometer was run in positive and negative full scan 355 356 mode at a resolution of 240,000 scanning from 50-750 m/z. Metabolite data were analyzed by El-MAVEN software package^{38,39}. Metabolites were identified by matching observed m/z signals (+/-357 358 10 ppm) and chromatographic retention times to those observed from a commercial metabolite 359 library of standards (MSMLS; Sigma-Aldrich). Assignments were verified on the Thermo Fisher 360 Q ExactiveTM HF platform via MS/MS fragmentation analysis and co-elution of standards with the identified signals from urine. 361

362 *Targeted mass spectrometry*

Targeted mass spectrometry analysis for validation of agmatine as a UTI biomarker and clinical 363 trial 1 was performed on a TSQ Quantum[™] Access MAX (Thermo Scientific). For quantitative 364 analyses the following transitions were monitored using a fixed collision energy of 15 eV: ¹²C 365 agmatine, $131.2 \rightarrow 72.4 \text{ m/z}$; [U-¹³C]agmatine, $136.2 \rightarrow 76.4 \text{ m/z}$ in positive ionization mode. The 366 367 same HPLC column and buffers were used as described above, with the following modified 6minute gradient: 0-0.5 min, 100% B; 0.5-2 min, 100-5% B; 2-3.5 min, 5-0% B; 3.5-4.5 min, 0% 368 B; 4.5–5 min, 0–100% B; 5–6 min, 100% B. For targeted experiments using the TSQ Quantum[™], 369 electrospray ionization source conditions were as follows: spray voltage of 3000 V, sheath gas of 370 371 25 (arbitrary units), auxiliary gas of 10 (arbitrary units), sweep gas of 0 (arbitrary units), capillary 372 temperature of 275 °C, auxiliary gas temperature of 325 °C.

373 *Dilute and shoot*

374 For clinical trial 2 ("dilute and shoot" approach), LC-MS/MS analysis was performed on a Vanquish[™] UHPLC system, with an integrated Vanquish[™] charger module (Thermo Scientific). 375 376 coupled to a TSO Altis[™] triple quadrupole mass spectrometer (Thermo Scientific) equipped with 377 an electrospray ionization (HESI-II) probe. The UHPLC-MS platform was controlled by an Xcalibur[™] data system (Thermo Scientific). Chromatographic separation was achieved on a 378 379 Syncronis[™] HILIC column (50 X 2.1 mm, 1.7 µm, Thermo Fisher Scientific) using a binary solvent system composed of LC-MS grade H₂O with 20 mM ammonium formate, pH3 (solvent A) 380 and LC-MS grade acetonitrile with 0.1% (%v/v) formic acid (solvent B). The following 3.2 min 381 382 gradient was used: 0-0.5 min, 95% B; 0.5-1.75 min, 95-30% B; 1.75-1.8 min, 30-5% B; 1.8-2.3 min, 5% B; 2.3-2.4 min, 5-95% B; 2.4-3.2 min, 95% B. The flow rate was 1 mL min⁻¹ and the 383 384 sample injection volume 2 µL. The auto sampler and charger were kept at 6 °C and the column at 385 30 °C. For quantitative analyses the following transitions were monitored using the following polarities, collision energies and transitions: agmatine, positive, 16 eV, $131.0 \rightarrow 97.1 \text{ m/z}$; N6-386 387 methyladenine, positive, 23 eV, $150.0 \rightarrow 122.9 \text{ m/z}$; creatinine, positive, 13 eV, $114.1 \rightarrow 86.1 \text{ m/z}$. 388 Electrospray ionization source conditions were as follows: spray voltage of 3000 V (2500 V, 389 negative mode), vaporizer temperature of 250 °C, sheath gas of 35 (arbitrary units), auxiliary gas 390 flow of 15(arbitrary units) and sweep gas flow of 2 (arbitrary units), capillary temperature of 275 °C. 391

392 Determination of agmatine threshold values using $[U^{-13}C]$ agmatine

Targeted quantitative analysis was conducted to establish agmatine thresholds between culture positive and culture negative urine samples (Validation of agmatine as a UTI marker) and to assess performance thresholds (Clinical cohort 1). Quantitative analyses of agmatine in 519 urine samples was undertaken using a known concentration of a $[U^{-13}C]$ agmatine isotope as an internal standard in the urine sample (see $[U^{-13}C]$ agmatine standard biosynthesis and purification below). Prior to MS analysis, samples were purified using a solid phase extraction (SPE) 96-well HyperSepTM Silica

399 plate. Columns were equilibrated with methanol followed by water, then loaded with the sample of 400 interest. Columns were then washed with methanol, water, methanol with 0.1% formic acid, water 401 with 0.1% formic acid. The target analyte was eluted with water containing 2% formic acid. LC-402 MS analysis was performed using a TSQ Quantum[™] Access MAX Triple Quadrupole Mass 403 Spectrometer (Thermo Scientific). For the clinically-adapted blinded evaluation, clinical urine 404 specimens were centrifuged and the supernatant was spiked with the [U-¹³C]agmatine isotope. 405 These samples were analyzed directly on a TSQ Quantum[™] Access MAX instrument.

406

407 $[U^{-13}C]$ agmatine standard biosynthesis and purification

408 Escherichia coli (strain MG1665) was seeded into M9 minimal media containing 22.2 mM [U-¹³C]glucose, grown overnight, and was then seeded into fresh [U-¹³C]glucose-containing media. 409 This culture was then incubated under agitation in a 37 °C, 5% CO₂ incubator. Glucose 410 consumption was monitored using a blood glucose monitoring system (Bayer Contour Next). When 411 glucose levels in the media reached 5 mM, the culture was centrifuged, the supernatant was 412 retrieved, was adjusted to pH 7 with ammonium bicarbonate, and was steri-filtered. [U-413 ¹³C]agmatine was isolated and purified using a solid phase extraction column (HyperSepTM Silica 414 415 Cartridges, # 60108-712, Thermo Scientific), as described above and scaled accordingly to the column volume. The fraction was concentrated to 1/10th of its initial volume in a vacuum 416 concentrator at 4 °C and labeled [U-13C]agmatine in the final sample was quantified by stable 417 418 isotope dilution via LC-MS/MS using an unlabeled internal standard curve.

419 Validation of microbial metabolic capacity

420 E. coli and S. aureus were inoculated in sterilized urine to verify that agmatine and N6-

421 methyladenine originate from microbial metabolism. *In vitro* microbial samples were cultured from

- 422 reference strains of bacteria (*E. coli*: MG1665, ATCC 25922, ESBL ATCC BAA-196; *S. aureus*:
- 423 ATCC25923, ATCC 43300 (MRSA)). Briefly, cryogenic stocks were grown overnight in Mueller-

Hinton medium, then inoculated at 10⁵ CFU/mL in sterilized urine and grown at 37 °C. E. coli 424 cultures were spiked with [guanido- $^{15}N_2$]arginine (herein referred to as "[$^{15}N_2$]arginine") such that 425 the urine contained an approximate 1:1 ¹²C arginine to $[^{15}N_2]$ arginine ratio. The disappearance of 426 $[^{15}N_2]$ -arginine and appearance of [guanido- $^{15}N_2$]agmatine (herein referred to as " $[^{15}N_2]$ agmatine") 427 was monitored over five hours using LC-MS/MS. Similarly, the appearance of the N6-428 methyladenine signal was assessed in S. aureus cultures at 0, 4, 8, 10, and 12 hours with LC-MS. 429 To demonstrate that agmatine concentrations are proportional to microbial load, Muller Hinton 430 Medium was seeded with varying concentrations of E. coli (ATCC 25922; 10³-10⁸ CFU/mL) and 431 432 agmatine levels were measured following a 6-hour incubation period using the Q Exactive™ HF platform. Inhibition of agmatine production by boric acid preservative, at concentrations used in 433 434 BD Vacutainer Plus Tubes (2.63 mg/mL boric acid, 3.95 mg/mL sodium borate, 1.65 mg/mL 435 sodium formate) was monitored in filter sterilized urine seeded with E. coli (three reference strains - MG1665, ATCC 25922, ATCC BAA-196 - and four clinical isolates) over a 24-hour period and 436 437 analyzed on the Q Exactive[™] HF platform.

438 Blinded performance evaluation of agmatine versus traditional urine analysis pipeline

Mid-stream urine samples for the blinded head-to-head performance evaluation were collected from Alberta Precision Laboratories' standardized urine analysis workflow (described above in *Urine Sample Collection*). These samples were stripped of diagnostic information and assigned a unique identifier prior to their transfer to the analytical team. Following analysis using a clinically adapted metabolomics platform, diagnostic data were un-masked and the results of the quantitative agmatine-based MS approach were scored against the clinical diagnostic laboratory calls, using 174 nM as the threshold for UTI-positive samples.

446 Targeted quantitative assays were conducted in two independently blinded trials using slightly447 differing methods. In trial 1, targeted mass spectrometry was performed to quantify the levels of

agmatine in a blinded cohort of 587 urine specimens. This was done following the targeted mass
spectrometry workflow described above using spiked in [U-¹³C]agmatine and SPE sample cleanup.
In trial 2, 1,042 urine specimens were analyzed using a simplified dilute and shoot targeted
workflow that accurately captures the two target analytes as well as creatinine in a single injection.
This approach negates the use of solid phase extraction, and instead, a 1/20 dilution of the sample
was directly injected onto the MS following our chromatographic methods described above using
a 3.2-minute gradient and external agmatine standard curves were used for quantification.

455 *Data analysis and statistics*

456 Raw mass spectrometry files were converted into .mzXML files via MSConvertGUI (ProteoWizard Tools)⁴⁰. All full scan MS analyses were conducted in MAVEN. MS/MS data were 457 458 analyzed using Xcalibur 4.0.27.19 software (Thermo Scientific). Untargeted mass spectrometry 459 data were grouped according to co-variance, co-retention and similarity to common adducts/fragments using previously published software developed in R Statistics⁴¹. Violin plots, 460 ROC curves, and scatter plots were all generated in R Statistics using existing packages, (FUGU-461 MS, pROC, and vioPlot). A two-tail unequal variance Welch T-test was used to test differences in 462 agmatine and N6-methyladenine levels in culture positive urine samples compared to negative 463 controls. Alpha thresholds for significance were coerced for multiple hypothesis testing via 464 465 Bonferroni correction

466 **Data availability**

467 All data are available in the main text or the supplementary materials. Raw mass spectrometry data468 are available from the study team upon request.


470 **References**

471 472 473 474	1.	Fernández-García, M., Rojo, D., Rey-Stolle, F., García, A. & Barbas, C. Metabolomic-Based Methods in Diagnosis and Monitoring Infection Progression. in <i>Metabolic Interaction in Infection</i> (eds. Silvestre, R. & Torrado, E.) 283–315 (Springer International Publishing, Cham, 2018). doi:10.1007/978-3-319-74932-7_7.
475 476	2.	Satink, H. P. W. M. <i>et al.</i> Microbial influences on urinary polyamine excretion. <i>Clin Chim Acta</i> 179 , 305–314 (1989).
477 478 479	3.	Lussu, M. <i>et al.</i> 1H NMR spectroscopy-based metabolomics analysis for the diagnosis of symptomatic E. coli-associated urinary tract infection (UTI). <i>BMC Microbiol</i> 17 , 201 (2017).
480 481	4.	Bower, J. M. & Mulvey, M. A. Polyamine-mediated resistance of uropathogenic Escherichia coli to nitrosative stress. <i>J Bacteriol</i> 188 , 928–933 (2006).
482 483 484	5.	Puebla-Barragan, S., Renaud, J., Sumarah, M. & Reid, G. Malodorous biogenic amines in Escherichia coli-caused urinary tract infections in women—a metabolomics approach. <i>Sci Rep</i> 10 , 9703 (2020).
485	6.	Bouatra, S. et al. The Human Urine Metabolome. PLoS One 8, e73076 (2013).
486 487 488	7.	Laupland, K. B., Ross, T., Pitout, J. D. D., Church, D. L. & Gregson, D. B. Community- onset urinary tract infections: A population-based assessment. <i>Infection</i> 35 , 150–153 (2007).
489 490 491	8.	Alberta Precision Laboratories. <i>Change of Urine Colony Count Format</i> . https://www.albertahealthservices.ca/assets/wf/lab/if-lab-hp-bulletin-change-of-urine-colony-count-format.pdf (2021).
492 493 494	9.	Lu, CD. Pathways and regulation of bacterial arginine metabolism and perspectives for obtaining arginine overproducing strains. <i>Applied Microbiology and Technology</i> 70 , 261–272 (2006).
495 496 497	10.	Mohapatra, S. S. & Biondi, E. G. DNA Methylation in Prokaryotes: Regulation and Function. in <i>Cellular Ecophysiology of Microbe</i> (ed. Krell, T.) 1–21 (Springer, Cham, 2017). doi:10.1007/978-3-319-20796-4_23-1.
498 499	11.	Adaway, J. E., Keevil, B. G. & Owen, L. J. Liquid chromatography tandem mass spectrometry in the clinical laboratory. <i>Ann Clin Biochem</i> 52 , 18–38 (2015).
500 501 502	12.	Chan, W. W. Urine Cultures. in <i>Clinical Microbiology Procedures Handbook</i> (ed. Leber, A. L.) 3.12.1-3.12.33 (ASM Press, Washington, DC, 2016). doi:10.1128/9781555818814.CH3.12.
503 504 505	13.	Leis, J. A. <i>et al.</i> Choosing Wisely Canada—Top five list in medical microbiology: An official position statement of the Association of Medical Microbiology and Infectious Disease (AMMI) Canada. <i>JAMMI</i> 3 , 61–70 (2018).
506 507	14.	Arndt, T. Urine-creatinine concentration as a marker of urine dilution: reflections using a cohort of 45,000 samples. <i>Forensic Sci Int</i> 186 , 48–51 (2009).

- 508 15. Barr, D. B. *et al.* Urinary Creatinine Concentrations in the U.S. Population: Implications
 509 for Urinary Biologic Monitoring Measurements. *Environ Health Perspect* 113, 192–200
 510 (2005).
- 511 16. Chu, C. M. & Lowder, J. L. Diagnosis and treatment of urinary tract infections across age
 512 groups. *Am J Obstet Gynecol* 219, 40–51 (2018).
- 513 17. Schappert, S. M. & Rechtsteiner, E. A. Ambulatory medical care utilization estimates for
 514 2007. *Vital and Health Stats. 13* 1–38 (2011).
- 515 18. Wilson, M. L. & Gaido, L. Laboratory diagnosis of urinary tract infections in adult
 516 patients. *Clinical Infectious Diseases* 38, 1150–1158 (2004).
- 517 19. Holmes, A. H. *et al.* Understanding the mechanisms and drivers of antimicrobial
 518 resistance. *The Lancet* 387, 176–187 (2016).
- 519 20. Andersson, D. I. & Hughes, D. Microbiological effects of sublethal levels of antibiotics.
 520 Nat Rev Microbiol 12, 465–478 (2014).
- 521 21. Costelloe, C., Metcalfe, C., Lovering, A., Mant, D. & Hay, A. D. Effect of antibiotic
 522 prescribing in primary care on antimicrobial resistance in individual patients: systematic
 523 review and meta-analysis. *BMJ* 340, c2096 (2010).
- 524 22. O'Neill, J. Rapid Diagnostics: Stopping Unnecessary Use of Antibiotics. *Review on* 525 *Antimicrobial Resistance* (2015).
- Waller, T. A., Pantin, S. A. L., Yenior, A. L. & Pujalte, G. G. A. Urinary Tract Infection
 Antibiotic Resistance in the United States. *Primary Care Clinics in Office Practice* 45, 455–466 (2018).
- 529 24. Laxminarayan, R. *et al.* Antibiotic resistance-the need for global solutions. *Lancet Infect*530 *Dis* 13, 1057–1098 (2013).
- 531 25. Maxim, L. D., Niebo, R. & Utell, M. J. Screening tests: A review with examples. *Inhal Toxicol* 26, 811–828 (2014).
- 533 26. Kitto, K. & Colledge, E. Urinary Tract Infections in Adults. *Family & Community* 534 *Medicine University of Toronto* 1–2 Preprint at http://thehub.utoronto.ca/family/wp 535 content/uploads/2018/03/Urinary-Tract-Infections-in-Adults.pdf (2011).
- 536 27. Flores-Mireles, A. L., Walker, J. N., Caparon, M. & Hultgren, S. J. Urinary tract
 537 infections: Epidemiology, mechanisms of infection and treatment options. *Nat Rev*538 *Microbiol* 13, 269–284 (2015).
- 539 28. Jannetto, P. J. & Fitzgerald, R. L. Effective use of mass spectrometry in the clinical laboratory. *Clin Chem* 62, 92–98 (2016).
- 541 29. Huisman, H., Wynveen, P., Nichkova, M. & Kellermann, G. Novel ELISAs for screening
 542 of the biogenic amines GABA, glycine, β-phenylethylamine, agmatine, and taurine using
 543 one derivatization procedure of whole urine samples. *Anal Chem* 82, 6526–6533 (2010).


544 545 546	30.	Semeniuk, H. & Church, D. Evaluation of the Leukocyte Esterase and Nitrite Urine Dipstick Screening Tests for Detection of Bacteriuria in Women with Suspected Uncomplicated Urinary Tract Infections. <i>J Clin Microbiol</i> 37 , 3051–3052 (1999).			
547 548	31.	Nicolle, L. E. Asymptomatic bacteriuria: When to screen and when to treat. <i>Infect Dis Clin North Am</i> 17 , 367–394 (2003).			
549 550	32.	Dong, X. <i>et al.</i> Thermogenic hydrocarbon biodegradation by diverse depth-stratified microbial populations at a Scotian Basin cold seep. <i>Nat Commun</i> 11 , 5825 (2020).			
551 552	33.	Mager, L. F. <i>et al.</i> Microbiome-derived inosine modulates response to checkpoint inhibitor immunotherapy. <i>Science (1979)</i> 369 , 1481–1489 (2020).			
553 554	34.	Rydzak, T. <i>et al.</i> Metabolic preference assay for rapid diagnosis of bloodstream infections. <i>Nat Commun</i> 13 , 2332 (2022).			
555 556 557	35.	Groves, R. A. <i>et al.</i> Methods for Quantifying the Metabolic Boundary Fluxes of Cell Cultures in Large Cohorts by High-Resolution Hydrophilic Liquid Chromatography Mass Spectrometry. <i>Anal Chem</i> 94 , 8874–8882 (2022).			
558 559 560	36.	Mohammadi, M. <i>et al.</i> Microbial containment device: A platform for comprehensive analysis of microbial metabolism without sample preparation. <i>Front Microbiol</i> 13 , 1–13 (2022).			
561 562 563	37.	Mapar, M., Rydzak, T., Groves, R. A. & Lewis, I. A. Biomarker enrichment medium: A defined medium for metabolomic analysis of microbial pathogens. <i>Front Microbiol</i> 13 , 657158 (2022).			
564 565 566	38.	Clasquin, M. F., Melamud, E. & Rabinowitz, J. D. LC-MS Data Processing with MAVEN: A Metabolomic Analysis and Visualization Engine. <i>Curr Protoc Bioinformatics</i> 37 , 14.11.1-14.11.23 (2012).			
567 568	39.	Melamud, E., Vastag, L. & Rabinowitz, J. D. Metabolomic analysis and visualization engine for LC–MS data. <i>Anal Chem</i> 82 , 9818–9826 (2010).			
569 570	40.	Chambers, M. C. <i>et al.</i> A cross-platform toolkit for mass spectrometry and proteomics. <i>Nat Biotechnol</i> 30 , 918–920 (2012).			
571 572	41.	R Core Team. R: A Language and Environment for Statistical Computing. Preprint at https://www.r-project.org/ (2019).			
573					
574	Ackn	owledgments			
575 576	This work was supported by a Genomics Application Partnership Program award from Genome				
577	Canada (10019200), Genome Alberta (10021232), Canadian Institute of Health Research				
578	(10020019), and the 2017 Large Scale Applied Research Project competition. This work was made				
579	possi	ble in part by a research collaboration agreement with Thermo Fisher Scientific. IAL was			

580	supported by an Alberta Innovates Translational Health Chair (10010625). TR was supported by
581	an Eyes High Postdoctoral Fellowship from the University of Calgary (10011121). S.D.W. was
582	supported in part by an NSERC Undergraduate Summer Research Award. Metabolomics data were
583	acquired at the Calgary Metabolomics Research Facility, which is part of the Alberta Centre for
584	Advanced Diagnostics (ACAD; PrairiesCan RIE #22734) and is supported by the International
585	Microbiome Centre and the Canada Foundation for Innovation (CFI-JELF 34986)
586	
587	Author Contributions
588	S.D.W., C.C.Y.C., D.B.G., D.G.B., T.R., and I.A.L. designed and performed the experiments
589	S.D.W., D.B.G., D.G.B., C.C.Y.C., R.A.G., D.B.G., R.A., and T.R. collected and interpreted mass
590	spectrometry data. K.P., N.V.B., and I.A.L. interpreted results wrote the manuscript in consultation
591	with all authors.
592	
593	Competing Interest Statement
594	Drs. Lewis, Gregson and Mr. Groves are authors on a patent relating to the use of LC-MS for
595	detecting urinary tract infections. No other competing interests declared.



598 Figure 1. Discovery of agmatine and N6-methyladenine as UTI biomarkers. (a) LC-MS data were acquired from metabolites predictive of culture-positive (yellow points) and culture-599 600 negative (purple points) urine samples. Potential UTI biomarkers were identified (m/z 131.1289 601 and m/z 150.0772 shown as example; see inset for chromatogram). (b) Predictive UTI biomarkers 602 were ranked according to receiver operating characteristic (ROC) curves. Signal 1 (m/z 114.1025) 603 and signal 2 (m/z 131.1289) were assigned to agmatine, and signal 3 (m/z 150.0771) was assigned 604 to N6-methyladenine. (c) Agmatine and (d) N6-methyladenine assignments were verified by 605 tandem LC-MS/MS fragmentation patterns observed in a culture-positive urine sample (i, iv), an 606 analytical standard of the target molecule (ii; 250 nM, v; 50 μ M), and a standard added to a


- 607 culture-negative urine sample at the same concentration (iii, vi). Abbreviations: Agm, agmatine;
- 608 6-MA, N6-methyladenine; Neg, growth-negative urine; Pos, growth-positive urine.




611 Figure 2. Microbial metabolite signals differentiate *Enterobacterales* and certain non-


612 *Enterobacterales* positive urines from controls. (a) Violin plot of agmatine concentrations in

- 613 urine samples determined by spike-in of stable isotope-labeled internal standard following SPE
- 614 (see inset). White dots indicate median values, thick black bars indicate interquartile ranges, and
- 615 thin black lines indicate 3x interquartile hinge points. (b) Violin plot of N6-methyladenine signal
- 616 intensities from a prospectively collected non-*Enterobacterales* cohort of patient urine samples.
- 617 (c) Three *E. coli* strains grown in sterile urine spiked with $[^{15}N_2]$ arginine for eight hours (top)
- 618 were monitored for $[^{15}N_2]$ agmatine production. Two *S. aureus* strains grown in sterile urine for 12
- hours (bottom) and were monitored for N6-methyladenine production. Abbreviations: Agm,
- agmatine; AUC, area under curve; CI, confidence interval; Thresh, threshold; PPV, positive
- 621 predictive value; NPV, negative predictive value; DCS, doubtful clinical significance; Non-ENT,
- 622 Non-Enterobacterales; ENT, Enterobacterales; STA, Staphylococcus species; AUR, Aerococcus
- 623 *urinae*; Arg, arginine; 6MA, N6-methyladenine; GBS, Group B Streptococci.



626





Sensitivity 6.0

0.2

0.0

1.0

0.8

0.6

ROC curve (AUC = 0.95) Agmatine ROC curve (AUC = 0.92) Agmatine/Creatinine

0.2

0.0

0.4

Specificity

6

8

-10

640

2


0

-2

DCSM SSB +

NGM2 238, J

In(Agmatine) (In(fM))



Marin 200) - Marin

642 specimens. (a) Violin plot of agmatine concentrations compared to creatinine normalized

- 643 agmatine concentrations. (b) Receiver operator curves demonstrating the equivalence between
- detected agmatine levels and creatinine normalized agmatine levels. Sensitivity and specificity 644
- 645 calculated for 0.17 µM threshold. Abbreviations: NG, no growth; DCS, doubtful clinical
- 646 significance; Non-ENT, Non-Enterobacterales; ENT, Enterobacterales; Mix, polymicrobial
- 647 cultures containing at least one *Enterobacterales* member; AUC, area under curve.